stoxline Quote Chart Rank Option Currency Glossary
Aligos Therapeutics, Inc. (ALGS)
0.451  0.035 (8.39%)    06-21 16:00
Open: 0.42
High: 0.4906
Volume: 465,187
Pre. Close: 0.4161
Low: 0.419
Market Cap: 34(M)
Technical analysis
2024-06-21 4:50:31 PM
Short term     
Mid term     
Targets 6-month :  0.72 1-year :  0.88
Resists First :  0.62 Second :  0.75
Pivot price 0.52
Supports First :  0.4 Second :  0.34
MAs MA(5) :  0.45 MA(20) :  0.54
MA(100) :  0.77 MA(250) :  0.77
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  6.9 D(3) :  3.6
RSI RSI(14): 28.4
52-week High :  1.2 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALGS ] has closed above bottom band by 20.9%. Bollinger Bands are 4.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.49 - 0.5 0.5 - 0.5
Low: 0.41 - 0.42 0.42 - 0.42
Close: 0.45 - 0.45 0.45 - 0.46
Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Headline News

Fri, 21 Jun 2024
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Lifestyle Singapore

Fri, 14 Jun 2024
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 69.1% in May - Defense World

Tue, 04 Jun 2024
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

Tue, 04 Jun 2024
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 - Investing News Network

Fri, 24 May 2024
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St

Wed, 15 May 2024
Aligos Therapeutics Announces Chief Medical Officer Resignation - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 75 (M)
Held by Insiders 4.021e+007 (%)
Held by Institutions 20.5 (%)
Shares Short 657 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -8.414e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 235.8 %
Return on Equity (ttm) -42.9 %
Qtrly Rev. Growth 1.379e+007 %
Gross Profit (p.s.) -27.99
Sales Per Share -60.44
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -79 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.3
Stock Dividends
Dividend 0
Forward Dividend 1.1e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android